BCL2 and non-Hodgkin lymphoma: The tumorigenic potential of aberrant Bcl-2 protein expression was first associated with poor outcomes in non-Hodgkin’s lymphoma, [19] and Bcl-2 overexpression was further identified in various solid tumors.